BCRT Independent Scientific Advisory Panel

BCRT has funded over £1.5 million of research grants since 2006. We hold two grant rounds per year, where we accept grant applications from researchers across the UK and Ireland. These applications undergo a process called ‘external peer review’, whereby the applications are sent to experts in the same field of research. These experts are from all over the world and we thank them for their time.

The applications and their peer reviews are then considered by the Independent Scientific Advisory Panel (ISAP). The ISAP makes a set of recommendations to the Board of Trustees about which grant applications should be funded.

BCRT is very grateful to the members of the ISAP, who kindly give their time to assess the grant applications and make recommendations to BCRT’s Board of Trustees about which applications should be funded.

ISAP Chair: Professor Andy Hall

The ISAP is chaired by Professor Andy Hall. Andy is Professor of Experimental Haematology at Newcastle University and Honorary Consultant Haematologist at the Newcastle upon Tyne NHS Foundation Trust. Andy’s research focusses on acute lymphoblastic leukaemia (ALL), which is the biggest cause of cancer deaths in young people under the age of 15. Some cases of ALL fail to respond to chemotherapy and Andy’s research has helped us to understand how this resistance to chemotherapy happens, and how it can be tackled to improve survival rates.

ISAP members

Mr Simon Allocca is a lay-member of the ISAP. Simon’s daughter Rose sadly passed away in 2010 after a brave fight against osteosarcoma. The Allocca family are dedicated supporters and fundraisers for BCRT and their ‘Run For Rose’ team in the 2012 Royal Parks Half Marathon raised over £30,000 for BCRT in Rose’s memory.

Professor Bob Brown is Professor of Translational Oncology at the Institute of Cancer Research and Imperial College London. Bob’s research focusses on how cancer cells can escape the effects of chemotherapy drugs, and how changes to the way that genes are controlled (epigenetic changes) can determine whether a cancer will respond to chemotherapy or not.

Dr Richard Grose is a Senior Lecturer in Cell Biology at Barts Cancer Institute, Queen Mary University of London. Richard’s research focusses on how cells communicate with each other via the release and detection of molecular signals, and how the normal processes of cell signalling can be hijacked in cancer cells to drive tumour growth.

Professor Pamela Kearns is Professor of Clinical Paediatric Oncology at the University of Birmingham and an Honorary Consultant Paediatric Oncologist at the Birmingham Children’s Hospital. Pamela is the Director of the Cancer Research UK Clinical Trials Unit and her research focusses on developing new therapies for childhood leukaemias.

Dr Dan Stark is a Teenage and Young Adult Oncologist at St James’s Hospital in Leeds, where he treats patients with a range of cancers. Dan takes part in national expert groups to develop cancer services for teenagers and young adults, and his research focusses on identifying ways to support cancer patients.

A A A